Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion’s independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company’s interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion’s Board.

This appointment by the Board of directors is performed by way of co-optation, the mandate of Amit Munshi to replace John Furey will be submitted to Sensorion’s shareholders for ratification at the Company’s next General Meeting.

Khalil Barrage said: “On behalf of my fellow Board members and the management team, it’s a pleasure to welcome Amit to Sensorion as our new Chairman. His extraordinary track record of building companies by executing multi-faceted corporate growth strategies that integrate capital markets, business development and M&A will be invaluable to the Company as we advance our portfolio of game-changing therapeutic programs for hearing disorders and remain steadfast in our mission to be the global leader in the field. I also wish to extend gratitude to John for his outstanding contributions to Sensorion over the past six years.”

Amit Munshi brings to Sensorion approximately 35 years of experience in the healthcare industry with specific expertise in executive leadership having led multiple biotech companies to successful transformational growth milestones and exits. Amit was most recently the Chief Executive Officer of Orna Therapeutics, and previously ReNAgade Therapeutics which was acquired by Orna in May 2024. Amit’s career includes serving as President and CEO of Arena Therapeutics (Nasdaq:ARNA) commencing in 2016, where he led the company’s transformation from a $300M market cap company into a late clinical stage organization, before its $6.7B acquisition by Pfizer (March 2022). During his tenure at Arena, Amit also spun-out assets into Longboard Therapeutics (NASDAQ: LBPH; recently acquired by Lundbeck AS for $2.6B). He was the co-founder and Chief Business Officer of Kythera Biopharmaceuticals, Inc (Nasdaq:KYTH), where he identified the lead asset (Kybella), led several rounds of financing and completed a $370M ex-North America license transaction with a division of Bayer. KYTH was sold to Allergan (NYSE:AGN) for $2.1B (June 2015). Additional corporate leadership highlights include multiple roles at Big Pharma such as an 8-year tenure at Amgen Inc. where Amit was the General Manager of the Company’s European Nephrology Business Unit based in Switzerland with responsibility for Aranesp and Mimpara/Sensipar. Prior to his time in Switzerland, Amit was responsible for Amgen’s inflammation / immunology marketing including the launch of Kineret and the acquisition of Immunex Corp (Nasdaq:IMNX). Amit received an MBA from The Peter Drucker Graduate School of Management at Claremont Graduate University and holds a BA in History and a BS in Quantitative Economics from the University of California, Riverside.